DK1173418T3 - Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid - Google Patents

Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid

Info

Publication number
DK1173418T3
DK1173418T3 DK00926805T DK00926805T DK1173418T3 DK 1173418 T3 DK1173418 T3 DK 1173418T3 DK 00926805 T DK00926805 T DK 00926805T DK 00926805 T DK00926805 T DK 00926805T DK 1173418 T3 DK1173418 T3 DK 1173418T3
Authority
DK
Denmark
Prior art keywords
methoxy
methylaminothiocarbonyl
aminosulfonylphenyl
benzamide
chloro
Prior art date
Application number
DK00926805T
Other languages
Danish (da)
English (en)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Harald Schneider
Tobias Metzenthin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1173418T3 publication Critical patent/DK1173418T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00926805T 1999-04-16 2000-04-04 Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid DK1173418T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (1)

Publication Number Publication Date
DK1173418T3 true DK1173418T3 (da) 2006-04-10

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926805T DK1173418T3 (da) 1999-04-16 2000-04-04 Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid

Country Status (33)

Country Link
US (1) US6723751B1 (et)
EP (2) EP1173418B1 (et)
JP (1) JP4662640B2 (et)
KR (1) KR100700302B1 (et)
CN (1) CN1168712C (et)
AR (1) AR023479A1 (et)
AT (2) ATE414059T1 (et)
AU (1) AU773246B2 (et)
BR (1) BR0010658A (et)
CA (1) CA2370388C (et)
CZ (1) CZ302459B6 (et)
DE (3) DE19917233A1 (et)
DK (1) DK1173418T3 (et)
EE (1) EE04612B1 (et)
ES (1) ES2251996T3 (et)
HK (1) HK1046270B (et)
HR (1) HRP20010744B1 (et)
HU (1) HU229082B1 (et)
IL (2) IL145921A0 (et)
ME (1) MEP55708A (et)
MX (1) MXPA01010275A (et)
MY (1) MY122588A (et)
NO (1) NO327798B1 (et)
NZ (1) NZ514788A (et)
PL (1) PL203809B1 (et)
RS (1) RS50916B (et)
RU (1) RU2235089C2 (et)
SI (1) SI1173418T1 (et)
SK (1) SK287175B6 (et)
TR (2) TR200102993T2 (et)
TW (1) TWI276622B (et)
WO (1) WO2000063167A1 (et)
ZA (1) ZA200108400B (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542852A (en) * 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098069T3 (es) * 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU762832B2 (en) * 1998-09-10 2003-07-03 Sanofi-Aventis Deutschland Gmbh Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers

Also Published As

Publication number Publication date
AU773246B2 (en) 2004-05-20
MEP55708A (en) 2011-05-10
CZ302459B6 (cs) 2011-06-01
EP1637519A1 (en) 2006-03-22
HK1046270B (zh) 2005-03-11
EE04612B1 (et) 2006-04-17
PL351245A1 (en) 2003-04-07
SI1173418T1 (sl) 2006-02-28
RS50916B (sr) 2010-08-31
DE19917233A1 (de) 2000-10-19
PL203809B1 (pl) 2009-11-30
DE60024431D1 (en) 2006-01-05
MY122588A (en) 2006-04-29
JP2002542230A (ja) 2002-12-10
ZA200108400B (en) 2003-04-30
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
HRP20010744B1 (en) 2010-08-31
NO20015014L (no) 2001-10-15
ES2251996T3 (es) 2006-05-16
EP1637519B1 (en) 2008-11-12
SK14582001A3 (sk) 2002-01-07
CA2370388A1 (en) 2000-10-26
DE60024431T2 (de) 2006-07-27
MXPA01010275A (es) 2003-07-21
TR200501142T2 (tr) 2005-08-22
ATE414059T1 (de) 2008-11-15
HK1046270A1 (en) 2003-01-03
NZ514788A (en) 2003-03-28
HUP0200791A2 (hu) 2002-07-29
ATE311364T1 (de) 2005-12-15
US6723751B1 (en) 2004-04-20
SK287175B6 (sk) 2010-02-08
AR023479A1 (es) 2002-09-04
WO2000063167A1 (en) 2000-10-26
HRP20010744A2 (en) 2003-04-30
TWI276622B (en) 2007-03-21
KR100700302B1 (ko) 2007-03-29
CN1354744A (zh) 2002-06-19
IL145921A0 (en) 2002-07-25
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CN1168712C (zh) 2004-09-29
EP1173418A1 (en) 2002-01-23
IL145921A (en) 2006-07-05
BR0010658A (pt) 2002-02-19
CA2370388C (en) 2009-10-13
CZ20013672A3 (cs) 2002-01-16
NO20015014D0 (no) 2001-10-15
TR200102993T2 (tr) 2002-03-21
NO327798B1 (no) 2009-09-28
DE60040811D1 (de) 2008-12-24
YU72001A (sh) 2004-07-15
HU229082B1 (hu) 2013-07-29
EP1173418B1 (en) 2005-11-30
EE200100532A (et) 2002-12-16

Similar Documents

Publication Publication Date Title
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
IS2019B (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
NO20030550D0 (no) 17<beta>-karbotioat 17<alfa>-arylkarbonyloksyandrostanderivat som anti-inflammatoriske midler
NL350038I1 (nl) Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazoline derivaten
DK1140034T3 (da) Formulering af divalproex-natrium med kontrolleret frigivelse
EE200000584A (et) Viirusevastase bensimidasoolühendi kristallilisedvormid
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
HUP0202536A3 (en) Crystals of the sodium salt of pravastatin
NO20013684D0 (no) Substituerte fenetylaminderivater
ATE261431T1 (de) Kristalline form von (s)-2-ethoxy-3-4-(2-4- methansulfonyloxyphenyl-ethoxy)phenyl)propansäu e
DK1233960T3 (da) Polymorft salt af anti-migræne lægemiddel
DK1173418T3 (da) Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid
EE200100381A (et) Morfolinobensamiidi uued soolad
MA26840A1 (fr) Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
IS5544A (is) Nýtt fosfatsalt af ísóprópýl-metýl-[2-(3-n-própoxýfenoxý)-etýl]amíni
AR027876A4 (es) Juntas para la fijacion de herrajes en cristales
PL344006A1 (en) Α-(1-piperazinyl)acetamido arenecarboxylic acid derivatives as antidiabetic agents